|
|
||||||||
Department of Pathology, School of Medicine, University of Connecticut Health Center, Farmington, CT 06030
| Abstract |
|---|
|
|
|---|
55-kDa molecule under
nonreducing conditions but dissociates under reducing conditions.
Furthermore, the addition of rIL-7 or native IL-7 to medium conditioned
by stromal cells from IL-7 gene-deleted (-/-) mice results in the
formation of active 45-kDa and 55-kDa molecular complexes,
respectively. Antiserum prepared in IL-7(-/-) mice against
affinity-purified PPBSF contained separable reactivities for IL-7 and
the non-IL-7 component of PPBSF. The PPBSF cofactor detected by this
antiserum migrates as an
30-kDa molecule and is able to maintain the
viability, but not the proliferation, of pre-pro-B cells. Furthermore,
the cofactor is produced constitutively by IL-7(-/-) and IL-7(+/+)
bone marrow stromal cells under pro-B- but not pre-B-type culture
conditions. Consequently, IL-7 appears to exist almost entirely as a
heterodimer (i.e., PPBSF) in pro-B-type cultures, whereas it exists
almost entirely as a monomer in pre-B-type cultures. Although the
identity of the PPBSF cofactor remains to be determined, it does not
appear to be stem cell factor, insulin-like growth factor-1, thymic
stromal-derived lymphopoietin, flt3, stromal cell-derived factor-1, or
IL-7R. | Introduction |
|---|
|
|
|---|
Results of earlier studies have demonstrated that serum-free BM stromal cell conditioned medium (CM) from our culture system selectively stimulates the proliferation of pre-pro-B cells from freshly harvested rat BM and supports the accumulation, but not the proliferation, of pro-B cells in vitro (8). Adsorption of CM with anti-IL-7 mAb removes this activity, whereas rIL-7 restores this activity to CM by BM stromal cells from IL-7 gene-deleted mice (9). Furthermore, IL-7 with a nominal molecular mass of 25 kDa coisolates with pre-pro-B cell growth-stimulating activity in the apparent 50- to 100-kDa molecular mass fraction as determined by ultrafiltration. Yet IL-7 itself does not induce proliferation of pre-pro-B cells, even in the presence of stem cell factor (SCF) or insulin-like growth factor (IGF)-1, and anti-IL-7 mAb is unable to neutralize the growth-stimulating activity in CM. These results, in aggregate, suggested that the unique lymphopoietic properties of our BM lymphoid culture system were due to the presence of a molecular complex of IL-7 and a second stromal cell-derived factor. Although this molecular complex can also induce thymocyte proliferation (9), we have not yet detected its presence in thymic stromal cell CM (4, 8). Therefore, we have designated it pre-pro-B cell growth-stimulating factor (PPBSF).
The present study directly confirms, by Western blot analysis,
that PPBSF is an
55-kDa heterodimer that consists of one molecule of
IL-7 and one molecule of an as yet unidentified 30-kDa cofactor. The
results also demonstrate that the cofactor is constitutively produced
by IL-7(-/-) stromal cells under pro-B cell- but not pre-B cell-type
culture conditions and that it associates covalently with IL-7.
Finally, the results confirm our previous observation (9) that PPBSF
"primes" pre-pro-B cells and their immediate descendants to
proliferate in response to IL-7 alone. The possible role of PPBSF in
early B-lineage development and the exclusion of several candidates for
the PPBSF cofactor are discussed below.
| Materials and Methods |
|---|
|
|
|---|
Male 4- to 6-wk-old IL-7 gene-deleted (IL-7(-/-)) and nondeleted (IL-7(+/+)) mice (10) were bred from (129 x B6)F2 stock that was generously provided by Drs. Richard Murray and Ursula von Freeden-Jeffry (DNAX Research Institute of Cellular and Molecular Biology, Palo Alto, CA). The mice were used as donors of BM-adherent cells and stromal cell lines. Male 4- to 6-wk-old Lewis strain rats bred from stock originally obtained from the National Cancer Institute, National Institutes of Health (Bethesda, MD) were used as donors of BM lymphoid precursor cells.
Cytokines
rIL-7 was purchased from Genzyme Corporation (Cambridge, MA). Thymic stromal-derived lymphopoietin (TSLP) (11, 12) was generously provided by Dr. Philip J. Morrissey (Immunex Research and Development Corporation, Seattle, WA); rflt-3 ligand (13) was generously provided by Dr. Satish Menon (DNAX); and rSDF-1ß (14) was purchased from R&D Systems (Minneapolis, MN).
Antibodies
Neutralizing mAbs cross-reactive with both human and mouse IL-7 or SDF-1ß were purchased from Genzyme Corporation or R&D Systems, respectively. Rabbit polyclonal Abs against TSLP or mAbs against flt-3 ligand were kindly provided by Immunex or DNAX, respectively. Mouse IgG2b isotype control was obtained from Sigma (St. Louis, MO). Murine mAbs to the HIS40 (anti-IgM) (15), HIS24 (anti-CD45RC-B220) (16, 17), and HIS50 (anti-heat stable Ag (HSA)) (18) rat B-lineage-associated Ags were generously provided by Dr. Davine Opstelten (Department of Pathology, University of Hong Kong, Hong Kong, China). Mouse anti-bromodeoxyuridine (anti-BrdU) mAb (with nuclease) was purchased from Amersham International (Little Chalfont, U.K.). Affinity-purified FITC-conjugated goat IgG F(ab')2 anti-mouse IgM (heavy chain-specific) Ab was obtained from Kirkegaard and Perry Laboratories (Gaithersburg, MD). Affinity-purified rabbit Ab to calf thymus terminal deoxynucleotidyl transferase (TdT) as well as FITC- and tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-rabbit IgG were purchased from Supertechs (Bethesda, MD). Phycoerythrin-conjugated goat anti-mouse IgG was obtained from Caltag Laboratories (San Francisco, CA). Horseradish peroxidase (HRP)-linked sheep anti-mouse IgG or anti-rabbit IgG were purchased from Amersham Life Sciences (Arlington Heights, IL).
Immunofluorescence
Indirect immunofluorescence of cell surface Ags was performed by incubating 1 x 106 freshly harvested or culture-generated BM cells with mouse or rat primary Abs (10 µl) and developing with appropriate FITC- or phycoerythrin-conjugated goat anti-IgG or anti-IgM Abs. To detect intranuclear TdT, cytocentrifuge-prepared cell smears were fixed in 4°C absolute methanol, stained with rabbit Abs to TdT, and developed with FITC- or TRITC-conjugated Abs to rabbit IgG (19). Double immunofluorescence for Cµ or Sµ Ig heavy chains and TdT was performed on cell smears that were fixed in cold absolute ethanol with 5% glacial acetic acid for 20 min at 4°C, sequentially stained for TdT and HIS40, and developed with FITC goat anti-mouse IgG and TRITC goat anti-rabbit IgG (17).
To detect the incorporation of BrdU, cultured cells were pulsed overnight with BrdU cell-proliferation labeling reagent (Amersham International) in a final concentration of 1:1000. Cytosmears prepared from these cells were fixed in cold absolute ethanol with 5% glacial acetic acid, stained with the anti-BrdU/nuclease reaction mixture for 60 min, and developed with FITC goat anti-mouse IgG. Double immunofluorescence for BrdU and TdT was accomplished by staining for TdT at this step. Double immunofluorescence for BrdU and cell-surface Ags was performed by staining viable cells in suspension with the appropriate Abs and then staining cytocentrifuge smears of the same cells for BrdU.
Lymphoid culture systems
Pro-B-type cultures. Rat BM pre-pro-B cells and pro-B cells were generated in our culture system as previously described (4). Briefly, single cell suspensions of mouse BM (8 x 106 cells) were added to 2 ml RPMI 1640 containing 20% lot-selected, defined FBS (HyClone, Logan, UT) in 35-mm diameter culture plate wells and incubated at 37°C in 5% CO2. After 10 days, the confluent adherent cell layers were washed and seeded with 5 x 105 freshly harvested rat BM cells/ml. In some experiments, the rat BM cells were seeded into microporous membrane culture inserts (0.4-µm pore size; Transwell-3408, Costar, Cambridge, MA) that were placed over, but not in contact with, the mouse BM-adherent cell layers. Total cells from the culture inserts and nonadherent lymphoid cells from the standard cultures were recovered in serum-free medium on day 10 for cytologic and phenotypic analysis (8).
Pre-B-type cultures. Rat BM pre-B cells were generated in long-term culture by a modification of the method of Whitlock and Witte (20). Briefly, adherent cell layers were established by incubating 8 x 106 mouse BM cells/well at 37°C (5% CO2) in 2 ml RPMI 1640 medium containing 5% lot-selected, defined FBS (HyClone), 5 x 10-5 M 2-ME, and 40 mg/L gentamicin. The cultures were refed with 50% fresh medium twice weekly. After 20 days, the confluent adherent cell layers, containing only an occasional mouse lymphoid cell colony, were washed with RPMI 1640 and seeded with 5 x 105 freshly harvested rat BM cells/ml as above. Culture-generated lymphoid cells (>98% rat origin) were recovered on day 15 for cytologic and phenotypic analysis.
Conditioned medium
Washed confluent mouse BM-adherent cell layers or stromal cell lines therefrom were used to condition medium for 10 days (8). The CM for cell stimulation was filtered to remove any cells, concentrated twofold by ultrafiltration in Centriprep-10 concentrator units (Amicon, Danvers, MA), dialyzed for 16 h in serum-free normal medium at 4°C, and stored at -70°C. For cell stimulation, CM was diluted to twofold its original concentration with medium containing 20% FBS; for immunoadsorption or Western immunoblotting, 10x concentrated CM in serum-free normal medium was used.
Immunoadsorption of CM with anti-IL-7 mAb
Anti-IL-7 mAb (mouse IgG2b) was conjugated to protein A-Sepharose by incubating 15 µl of Ab with 80 µl of packed beads for 4 h. The beads were extensively washed with PBS to remove unbound Ab. Immunoadsorption was accomplished by incubating 10x concentrated CM with Ab-conjugated protein A-Sepharose beads (1 ml CM/80 µl packed beads) in a rotating mixer for 2 h at 4°C. The beads were pelleted in a microfuge (8000 rpm), and the supernatant was removed. This process was repeated three times. Nonspecific binding was controlled by incubating CM with unconjugated protein A-Sepharose beads and beads conjugated with a mouse IgG2b isotype control. The bound Ag was recovered from the beads by elution with 0.1 M NaHCO3 buffer (pH 9.3) containing 0.5 M NaCl, and the eluate was dialyzed for 16 h in PBS (pH 7.2) at 4°C.
Thymidine incorporation
To evaluate cell proliferation induced by CM, 1 x 105 freshly harvested rat thymocytes or day 10 culture-generated rat BM lymphoid cells were pulsed with 1 µCi/well of [3H]TdR (New England Nuclear, Boston, MA) 12 h before harvesting. Incorporation of [3H]TdR was determined by liquid scintillation spectroscopy.
Preparation of antisera to PPBSF
An anti-IL-7 immunoaffinity column was prepared by mixing 3 mg IL-7-specific mAb in coupling buffer with 0.3 g cyanogen bromide-activated Sepharose 4B according to the manufacturers instructions. One hundred milliliters of 10x concentrated serum-free CM was loaded onto the column, which was then washed with 50 ml PBS. The bound Ag was eluted with 10 ml of 0.1 M NaHCO3 buffer (pH 9.3) containing 0.5 M NaCl and dialyzed for 16 h in PBS (pH 7.2) at 4°C. The activity of the eluate was then tested by thymocyte proliferation analysis.
Equal volumes of eluate and Freunds adjuvant were mixed, and IL-7(-/-) mice were injected with a total of 2 ml eluate from IL-7(+/+) pro-B CM, IL-7(+/+) pre-B CM, or 20 µg rIL-7 at multiple s.c. sites on a biweekly basis. The first two biweekly immunizations were performed using Ag emulsified with CFA. All subsequent immunizations were carried out with the same Ag emulsified with IFA. After four successive biweekly immunizations, sera were collected and pooled. To remove anti-IL-7 Abs, some aliquots of antisera were adsorbed with rIL-7 coupled to cyanogen bromide-activated Sepharose 4B (5 µmol rIL-7/ml gel).
Western immunoblotting of CM for PPBSF
For Western immunoblotting, 25 µl of eluate from anti-IL-7, anti-PPBSF, or anti-IL-7 mAb-adsorbed anti-PPBSF Ab immunoaffinity columns was mixed with 25 µl of 2x SDS sample buffer, with or without 0.1 M DTT, and boiled for 5 min. The samples were loaded onto different slots of a 12% SDS-PAGE gel and run overnight at 45 V. The proteins were then transferred onto Immobilon-P membrane (Millipore, Bedford, MA) using a trans-Blot SD Semidry Transfer Cell (model 200/2.0, Bio-Rad, Hercules, CA) at 300 mA for 1 h. After blocking with 5% blocking reagent in PBS-Tween 20, the membrane was incubated with appropriate dilutions of anti-IL-7 mAb, anti-TSLP polyclonal Ab, anti-flt-3 ligand mAb, anti-SDF-1ß mAb, or antiserum to PPBSF; washed; incubated with 1:2000 HRP-labeled anti-mouse IgG or HRP-labeled anti-rabbit IgG; washed again; and developed with enhanced chemiluminescence Western blotting analysis system (Amersham Life Sciences).
| Results |
|---|
|
|
|---|
As previously documented (6) and illustrated in Figure 1
A, the pre-pro-B cell and
pro-B cell compartments in our culture system progressively expand with
time after inoculation with freshly harvested rat BM cells, whereas the
pre-B cell compartment progressively contracts. In contrast (Fig. 1
B), the pre-B cell compartment progressively expands
with time, after a brief lag, under Whitlock-Witte (W-W)-type culture
conditions (20), whereas the pre-pro-B cell and pro-B cell compartments
progressively contract, after a brief period of expansion. Therefore,
for convenience, these culture systems will be referred to as
pro-B-type and pre-B-type cultures, respectively.
|
The results in Figure 2
show that CM from
pro-B- and pre-B-type cultures supported the same patterns of
lymphopoiesis, albeit at lower efficiency, as cultures containing
BM-adherent cells (cf Figs. 1
A and 1B; day 11).
Furthermore, as shown in Figure 3
, the
growth-stimulating activity for thymocytes in pre-B CM, unlike that in
pro-B CM, was both neutralized and adsorbed by anti-IL-7 mAb. These
results suggested that the IL-7 in pre-B-type cultures, unlike that in
pro-B-type cultures, is not complexed with the cofactor previously
detected in IL-7(-/-) pro-B CM (9). To verify this, we evaluated the
ability of rIL-7 to restore PPBSF activity to IL-7(-/-) CM generated
under pre-B-type culture conditions. No activity for pre-pro-B cells
was detected (data not shown). The results below show that this was due
to the absence of the PPBSF cofactor from pre-B CM.
|
|
As shown in Figure 4
, the difference
in form of IL-7 in pro-B and pre-B CM was confirmed by electrophoresis
and Western immunoblotting. Under nonreducing conditions, the IL-7 in
pro-B CM migrated with a molecular mass of 55 kDa (lane
2, arrow), whereas that in pre-B CM migrated at 25 kDa
(lane 1). However, under reducing conditions,
the IL-7 in both pro-B and pre-B CM migrated as 25-kDa molecules.
Furthermore, the IL-7-associated molecule in pro-B CM did not
dissociate after treatment with 8 M urea, 1 M acetic acid, or 0.1 M
NaOH (Fig. 5
), suggesting that it exists
as a covalently bound (presumably disulfide-linked) molecular
complex.
|
|
To confirm that PPBSF is a self-associating heterodimer, rIL-7 was added to IL-7(+/+) and IL-7(-/-) CM generated under pro-B- and pre-B-type culture conditions. One hour later, the total amount of IL-7 in these CM was affinity purified, electrophoresed under nonreducing conditions, and subjected to Western blot analysis.
The results in Figure 6
show that all
detectable rIL-7 added to IL-7(-/-) pro-B CM (lane
5, arrow) migrated as part of a 45-kDa molecule, whereas the rIL-7
added to IL-7(+/+) pro-B CM (lane 3) migrated
at 14.5 kDa. This suggested that the rIL-7 formed a heterodimer with an
30-kDa molecule in IL-7(-/-) CM. Again, the endogenous IL-7 in
pro-B CM migrated as part of a 55-kDa molecule (lanes 2and 3). Conversely, all detectable rIL-7 added
to either IL-7(-/-) pre-B CM (lane 5, arrow) or
IL-7(+/+) pre-B CM (lane 3) migrated at 14.5
kDa, and the endogenous IL-7 migrated at 25 kDa (lanes 2and 3).
|
45 kDa) was
detected by Western blot analysis, even when rIL-7 was added in amounts
that ranged between 10-fold above and below that required for maximum
complex formation (data not shown).
Similarly, results in Figure 7
show that
native IL-7 in pre-B CM complexes with an
30-kDa molecule when added
to IL-7(-/-) pro-B CM (lane 3, arrow). However,
when mixed with IL-7(+/+) pro-B CM (lane 1),
native IL-7 continues to migrate as a 25-kDa molecule. The failure of
IL-7 to exist as a heterodimer in pre-B CM does not appear to be due to
an inhibitory effect of 2-ME on complex formation. This was shown by
the addition of 2-ME to pro-B CM. Under these conditions, 2-ME neither
caused the PPBSF in IL-7(+/+) CM to dissociate nor prevented rIL-7 from
forming PPBSF when added to IL-7(-/-) CM (data not shown). Therefore,
as confirmed below, the PPBSF cofactor appears to be absent from
pre-B CM.
|
Antisera were raised in IL-7(-/-) mice against Ags isolated from
IL-7(+/+) pro-B and pre-B CM by affinity purification with
anti-IL-7 mAb. The ability of these antisera to neutralize PPBSF
activity in pro-B CM was then tested against freshly harvested rat BM
cells. The results in Figure 8
show that
antiserum to the IL-7-associated Ag(s) in pro-B CM completely
neutralized PPBSF activity. Therefore, we have termed this
anti-PPBSF antiserum. However, the antisera to the IL-7-associated
Ag in pre-B CM and to rIL-7 itself did not neutralize PPBSF activity,
although both neutralized rIL-7 activity (data not shown).
|
55 kDa in IL-7(+/+) pro-B CM under nonreducing conditions
(lane 2), and two bands of
25 kDa
(asterisk) and 30 kDa (arrow) under reducing conditions. Only the
30-kDa band was observed in IL-7(-/-) pro-B CM (lane
4, arrows), and only the 25-kDa band was observed in IL-7(+/+)
pre-B CM (lane 1, asterisks). Neither band was
detected in IL-7(-/-) pre-B CM (lane 3).
Hence, the 30-kDa molecule was selectively produced under pro-B cell
culture conditions.
|
The PPBSF cofactor is not TSLP, flt3 ligand, or SDF-1
We have previously demonstrated that neither rSCF nor rIGF-1 can
substitute for the PPBSF cofactor in enabling IL-7 to induce
proliferation of pre-pro-B cells in vitro (9). Here, we determined
whether any of three other cloned cytokines/chemokines that synergize
with IL-7 in regulating early B-lineage development were identical with
the PPBSF cofactor. The results in Figure 10
show that neither TSLP (11, 12),
flt3 ligand (13), nor pre-B cell stimulation factor/SDF-1ß (14) is
detected by Western blot analysis using antiserum to the PPBSF
cofactor, and that the PPBSF cofactor is not detected by mAbs to TSLP,
flt3 ligand, or SDF-1ß. Furthermore, none of these
cytokines/chemokines formed a heterodimer when mixed with rIL-7 (data
not shown).
|
| Discussion |
|---|
|
|
|---|
30,000; 2) PPBSF can form in solution by the spontaneous association
of its two components; 3) the production of the two components of PPBSF
by BM stromal cells is independently regulated; but 4) the formation
and/or release of PPBSF under pro-B culture conditions is coordinated
such that little if any of either component normally appears in
monomeric form in the supernatant; and 5) the PPBSF cofactor, and
hence, PPBSF, is neither formed nor released under pre-B cell culture
conditions, thereby leaving only monomeric IL-7 in the supernatant.
Although the nature of the covalent binding reaction is not known,
dissociation of the PPBSF complex by DTT suggests that it occurs
through a disulfide/sulfhydryl exchange mechanism similar to that
observed in solution between platelet-derived growth factor and
2-macroglobulin (21). Functionally, 1) PPBSF stimulates
the proliferation of pre-pro-B cells and some thymocytes but not pro-B
cells or pre-B cells; 2) PPBSF primes pre-pro-B cells and their
immediate descendants to proliferate in the presence of IL-7 alone; and
3) both IL-7 and the PPBSF cofactor maintain the viability of
"unprimed" pre-pro-B cells, but neither induces their
proliferation. Having previously demonstrated that CM from pro-B-type cultures selectively stimulates the proliferation of pre-pro-B cells in vitro (8), the combined results of the present studies suggest that PPBSF, rather than IL-7 alone or in combination with SCF and/or IGF-1 (9), is the responsible agent. We also postulate that PPBSF normally induces the observed differentiation of pre-pro-B cells to pro-B cells (5, 6, 8, 22, 23). However, other cytokines, including monomeric IL-7 itself (9) and some as yet undefined SDFs, appear to amplify this process by inducing proliferation and/or differentiation of pro-B cells (2, 3, 11, 12, 13, 14, 24, 25, 26, 27, 28). Although none of these defined factors efficiently induces the development of pre-B cells in our culture system (our unpublished observations), such differentiation is rapidly induced in vitro by incubation of pro-B cells in IL-7(+/+) pre-B CM (29). Furthermore, surface IgM (sIgM)+ B cells appear in vivo within 2 wk of adoptive transfer of culture-generated pre-pro-B/pro-B cells to irradiated recipients (8; and our unpublished observations). Hence, additional factors not effectively represented in our culture system appear to be required for the differentiation of pro-B cells to pre-B cells (3, 14, 30, 31).
The observation that pro-B cells develop in IL-7 gene-deleted mice (10)
would appear to challenge the postulated role of PPBSF in early
B-lineage development. A more cautious interpretation, which we favor,
is that PPBSF is the preferred ligand under physiologic conditions but
that compensatory mechanisms for stimulating the proliferation and, at
the very least, the phenotypic differentiation of pre-pro-B cells exist
under nonphysiologic circumstances. Furthermore, such compensatory
mechanisms may be incomplete, given that phenotypic differentiation to
pro-B cells may occur in the absence of IgH gene rearrangements (32),
and that pro-B cell proliferation is markedly reduced in IL-7(-/-)
mice (C. Wei and I. Goldschneider, unpublished observations). It is
important to emphasize, therefore, that the in vivo administration of
anti-IL-7 mAb prevents the development of pro-B cells in normal
mice (33), and that pro-B cells apparently fail to develop in IL-7R
-chain (-/-) mice (34). Inasmuch as the absence of IL-7 itself
does not prevent pro-B cell formation (10), the former results suggest
that anti-IL-7 mAb causes the coordinate elimination of IL-7 and an
associated cofactor, thereby providing indirect evidence for the
existence of PPBSF in vivo (also see 35 . In addition, the latter
results suggest that the compensatory factor in IL-7(-/-) mice
transduces a signal via the IL-7R. An intriguing candidate is a
TSLP-like molecule (11, 12), whose function might be negatively
affected in IL-7R
-chain (-/-) mice. Whatever its identity, the
present results suggest that this compensatory factor is absent from
IL-7(-/-) stromal cell CM.
Regarding the nature of the PPBSF cofactor, the most obvious candidate
is the soluble form of the IL-7R (36), especially because other soluble
ligand-receptor complexes in the hemopoietin family have been found to
have enhanced functional activity over the ligand alone (37). Although
not formally excluded, this possibility seems unlikely for several
reasons. First, the form of the soluble IL-7R with the lowest molecular
mass thus far described (38) is still significantly greater than that
of the PPBSF cofactor. Second, the PPBSF cofactor appears to bind IL-7
covalently. Third, adsorption of CM with anti-IL-7R mAb does not
remove the PPBSF cofactor (our unpublished observations). Nevertheless,
it will be important to demonstrate that the PPBSF cofactor is produced
by BM stromal cells from IL-7R
-chain (-/-) mice.
Inasmuch as IL-7 is avidly bound by heparin (39), it is possible that the PPBSF cofactor is a component of the stromal cell-associated extracellular matrix in our culture system (5, 6). Despite our inability to detect PPBSF activity in extracellular matrices (ECMs) extracted from BM-adherent cell layers with hypertonic saline (8), continued efforts are warranted based upon reports of the regulation of growth-factor signaling by ECM proteins (40, 41) and especially the description by Oritani and Kincade (42) of a series of ECM glycoproteins that selectively increase the IL-7-dependent proliferation of pre-B cells.
A number of stromal cell-derived cytokines/chemokines that act synergistically with IL-7 have been described, and, based on molecular mass and certain functional attributes, at least some might theoretically be candidates for the PPBSF cofactor. Therefore, Western blot analysis was conducted to determine whether any of the candidates bind to IL-7 and/or cross-react serologically with the PPBSF cofactor. The negative results obtained with TSLP (11, 12), flt3 ligand (13), and pre-B cell stimulation factor/SDF-1 (14) appear to exclude these factors, and previous mixing experiments with rIL-7 have similarly excluded SCF and IGF-1 (9). Other IL-7-synergizing factors are similarly being analyzed. However, studies of the primary amino acid sequence of affinity-purified PPBSF cofactor are most likely to reveal its identity.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Present address: Department of Medicine, University of Pennsylvania School of Medicine, 909 Biomedical Research Building, 422 Curie Drive, Philadelphia, PA 19104. ![]()
3 Present address: Ares Advanced Technology, Inc., 280 Pond St., Randolph, MA 02368. ![]()
4 Address correspondence and reprint requests to Dr. I. Goldschneider, Department of Pathology, School of Medicine, University of Connecticut Health Center, Farmington, CT 06030-3105. E-mail address: ![]()
5 Abbreviations used in this paper: BM, bone marrow; CM, conditioned medium; PPBSF, pre-pro-B cell growth-stimulating factor; TSLP, thymic stromal-derived lymphopoietin; SDF, stromal cell-derived factor; HSA, heat-stable Ag; BrdU, bromodeoxyuridine; TRITC, tetramethylrhodamine isothiocyanate; SCF, stem cell factor; IGF, insulin-like growth factor; TdT, terminal deoxynucleotidyl transferase; ECM, extracellular matrix; sIgM, surface IgM; HRP, horseradish peroxidase. ![]()
Received for publication July 28, 1997. Accepted for publication November 4, 1997.
| References |
|---|
|
|
|---|
2-macroglobulin. Proc. Natl. Acad. Sci. USA 81:342.This article has been cited by other articles:
![]() |
C. D. Milne, S. A. Corfe, and C. J. Paige Heparan Sulfate and Heparin Enhance ERK Phosphorylation and Mediate preBCR-Dependent Events during B Lymphopoiesis J. Immunol., March 1, 2008; 180(5): 2839 - 2847. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Mackall A fine romance: IL-7 and HGFbeta Blood, March 1, 2006; 107(5): 1739 - 1740. [Full Text] [PDF] |
||||
![]() |
L. Lai, R. A. Zeff, and I. Goldschneider A recombinant single-chain IL-7/HGFbeta hybrid cytokine induces juxtacrine interactions of the IL-7 and HGF (c-Met) receptors and stimulates the proliferation of CFU-S12, CLPs, and pre-pro-B cells Blood, March 1, 2006; 107(5): 1776 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lai and I. Goldschneider Cutting Edge: Identification of a Hybrid Cytokine Consisting of IL-7 and the {beta}-Chain of the Hepatocyte Growth Factor/Scatter Factor J. Immunol., October 1, 2001; 167(7): 3550 - 3554. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wei, R. Zeff, and I. Goldschneider Murine Pro-B Cells Require IL-7 and Its Receptor Complex to Up-Regulate IL-7R{alpha}, Terminal Deoxynucleotidyltransferase, and c{micro} Expression J. Immunol., February 15, 2000; 164(4): 1961 - 1970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Veale, M. Raab, Z. Li, A. J. da Silva, S.-K. Kraeft, S. Weremowicz, C. C. Morton, and C. E. Rudd Novel Isoform of Lymphoid Adaptor FYN-T-binding Protein (FYB-130) Interacts with SLP-76 and Up-regulates Interleukin 2 Production J. Biol. Chem., October 1, 1999; 274(40): 28427 - 28435. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |